Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
Business Wire•10/11/2026•16:05 ET
0
Key Highlights
- ➤PDUFA target action date set for March 31, 2027
- ➤FDA approval could unlock Atara a $31 million Pierre Fabre milestone
- ➤Nine-month costs and operating expenses fell approximately 83% year over year
- ➤Third-quarter net loss narrowed to $2.2 million, or $0.15 per share
- ➤Cash, equivalents and short-term investments totaled $9.9 million; runway extends into mid-2027
Expert Statements
Cokey Nguyen, President and Chief Executive Officer of Atara Biotherapeutics
“The resubmission of the tab-cel BLA was an important milestone this quarter, and we remain focused on supporting Pierre Fabre Pharmaceuticals (PFP) toward a successful outcome”
Cokey Nguyen, President and Chief Executive Officer of Atara Biotherapeutics
“We continue to believe in tab-cel’s significant commercial potential in the U.S.”
Cokey Nguyen, President and Chief Executive Officer of Atara Biotherapeutics
“In parallel, we are taking steps to control expenses with the goal of protecting and maximizing shareholder value while enhancing our strategic flexibility.”
Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
Prescription Drug User Fee Act (PDUFA) Target Action Date of March 31, 2027
Get started
Create a free account to read the full story.